Articles
The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine are cytotoxic agents that have been widely used in the treatment of solid tumors. In the United States alone, an estimated 275,000 patients with cancer receive 5-FU each year. Despite its lifesaving/life-prolonging potential, 5-FU causes severe early-onset toxicity in up to one-fourth of patients, and more than 1300 die each year as a result of this toxicity. Read More ›
Although administration and toxicity may differ between the 2 agents, they share the same risks for early-onset toxicity and overdosage, the signs of which are easily dismissed by patients and providers as expected chemotherapy-related adverse events. Read More ›
Many healthcare providers who work in gastrointestinal oncology may feel blasé about the administration of 5-fluorouracil (5-FU), which is certainly the most commonly used chemotherapy in this setting. Read More ›
Although the 5-year survival rate for multiple myeloma is less than 50%, this type of cancer has witnessed a resurgence of drug therapies. Read More ›
Each year, >200,000 individuals in the United States are diagnosed with a primary or metastatic brain tumor. Primary brain tumors comprise approximately 40,000 of these diagnoses. Read More ›
Here's what you can expect to find in the August issue of The Oncology Pharmacist. Read More ›
By Chase Doyle
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer. Read More ›
By Chase Doyle
Childhood cancer therapy can be a double-edged sword; it often leads to a cure, but long after treatment ends, some survivors have treatment-related side effects. Read More ›
By Chase Doyle
The power to fight a virtually infinite array of pathogens is one of the hallmarks of the human immune system, and random diversity is its secret weapon. Read More ›
By Phoebe Starr
Adding the investigational drug indoximod, an indoleamine 2,3-dioxygenase (IDO) pathway inhibitor, to the checkpoint inhibitor pembrolizumab led to higher response rates in patients with advanced melanoma than what is reported with pembrolizumab monotherapy, Read More ›